Anthracyclines News and Research

RSS
Childhood cancer survivors more likely to have high blood pressure as adults

Childhood cancer survivors more likely to have high blood pressure as adults

Adipocytes may reduce effectiveness of chemotherapeutic drug

Adipocytes may reduce effectiveness of chemotherapeutic drug

Nebivolol treatment may protect against antracycline-induced cardiotoxicity in breast cancer patients

Nebivolol treatment may protect against antracycline-induced cardiotoxicity in breast cancer patients

ESC releases novel position paper on tackling cardiotoxicity of anticancer treatments

ESC releases novel position paper on tackling cardiotoxicity of anticancer treatments

Women undergoing breast cancer treatment are not getting recommended follow-up heart scans

Women undergoing breast cancer treatment are not getting recommended follow-up heart scans

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

AKR1C3 enzyme could be promising therapeutic target for managing CRPC, AML

AKR1C3 enzyme could be promising therapeutic target for managing CRPC, AML

Herceptin drugs for breast cancer linked with increased risk of congestive heart failure

Herceptin drugs for breast cancer linked with increased risk of congestive heart failure

MedUni Vienna researchers identify reason for chemoresistance in small cell lung cancer

MedUni Vienna researchers identify reason for chemoresistance in small cell lung cancer

PharmaMar begins PM184 Phase II trial in advanced breast cancer patients

PharmaMar begins PM184 Phase II trial in advanced breast cancer patients

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Research: New molecule safeguards heart from toxic breast cancer drugs, kills cancerous tumour

Research: New molecule safeguards heart from toxic breast cancer drugs, kills cancerous tumour

Study sheds light on clinical and biological characteristics of male breast cancer

Study sheds light on clinical and biological characteristics of male breast cancer

Combination therapy benefits patients with acute myeloid leukemia

Combination therapy benefits patients with acute myeloid leukemia

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

Update Pharma's UPI-928 gets FDA orphan drug designation for AML treatment

Update Pharma's UPI-928 gets FDA orphan drug designation for AML treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.